




Pharmacological means to improve 




Low mood and depression can be treated with many non-pharmacological means. However, in terminally 
ill these means are sometimes insufficient and the doctors need to prescribe drugs. In this article I shall 
discuss simple and proven drugs that improve patients mood and, some of them do have proven anti-
depressant activity. I shall discuss methylphenidate, ketamine, cannabinoids and buprenorphine in more 
detail. Cautious use of these drugs in different clinical situations may improve nearly instantly quality of 
life and quality of dying. However, unskilled use of some of them may result in earlier death, neurosis, 
epilepsy and even psychosis.
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Introduction
Terminally ill patients have many reasons to have 
their mood reduced or even being depressed. In fact, de-
pression is not uncommon in terminally ill and is frequ-
ently and specifically associated with desire to hasten 
death [1–4]. The reason for this can be looked at their 
poor existential prospects, but also increasing anxiety, 
pain and other symptoms, changing relationships with 
others, changing roles, but also everyday chores and 
problems which usually are met as a challenge, in ter-
minally ill they may be seen as impregnable bastions. 
Low mood (dysthymia) is a part of depression. 
However, low mood can occur without depression, is 
more volatile and has a tendency to change for better 
while depression is more established low mood, with 
a tendency to get better. Low mood can be associated 
with low self-esteem, worrying, tiredness, frustration 
and sadness. With time it may progress to major 
depression and  some other characteristics are being 
added to like hopelessness and helplessness, energy 
loss, pessimistic outlook, disturbed sleep pattern, 
social withdrawal and isolation, changes in appetite, 
suicidal or self-destructive thoughts. 
Primarily, the decreased mood should be treated 
with good pain and symptom control, attention to 
psychological, social and spiritual problems but not 
tackled pharmacologically. When these measures are 
inadequate and/or ineffective the doctor may consider 
pharmacological “boosting” of the mood.
This article will concentrate on the situations where 
the patients’ mood is depressed but there are no other 
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Many of these drugs that we propose have “high 
street value” and because of this are declined by our 
patients. Some mood enhancers, actually, taken often 
and in inappropriate doses may appear to be addictive 
or at least their effect may diminish in time perpetu-
ating feeling of hopelessness and defeat.
However, mood enhancing is certainly an option in 
patients with a limited prognosis who will die before 
experiencing an antidepressant effect of a tricyclic 
antidepressant. 
In this article I shall review a couple of drugs that 
may be used as mood enhancers in palliative care. 
The list of these drugs is long and it is increasing 
daily. I shall concentrate here on those few with 
confirmed efficacy and with which I personally have 
an experience (good or bad, does not matter). I shall 
not discuss typical antidepressants, which produce 
mood improvement as this literature is well known 
and does not need replication. 
Methylphenidate
Methylphenidate (MPH, Ritalin®) is a piperidine 
derivative structurally related to amphetamine. Phar-
macological effects are also similar to amphetamine. 
It belongs to mild CNS stimulants with more promi-
nent effects on mental than on motor activities. It has 
been used to treat opioid induced hypopnea, opioid 
induced sedation, attention deficits syndromes, cancer 
induced fatigue, recovery of the day and night rhythm 
(often adverse effects of opioids too) and more recen-
tly as mood enhancers and rapidly acting antidepres-
sant [8]. MPH shares with Amphetamine also potential 
of abuse and generalised convulsions. I personally 
treated one patient with bronchial carcinoma and 
opioid-induced sedation with MPH and this patient 
developed serious epileptic attack. After brain MRI we 
discovered multiple brain metastases. So it is possible 
that MPH may lower the threshold for convulsions in 
case of unknown brain pathology.
However, the most interesting is the mood en-
hancing and antidepressive property of MPH. The 
antidepressant effect of MPH has been noticed in early 
nineteen-sixties [9]. Since that time MPH had been 
used occasionally when the patients did not tolerate 
tricylics [10, 11]
In an open clinical trial 34 patients with major 
depressive disorders were challenged with dexame-
thasone suppression test and subsequently with MPH 
challenge. It appeared that patients who experienced 
suppressed cortisol levels after dexamethasone did 
not respond to MPH, but responded well to ami-
triptyline. The other group without cortisol depression 
after dexamethasone responded well to MPH and to 
means available to increase it other than drugs. This 
mood increase should happen rapidly and is needed 
only for a short time. We shall not discuss the cogniti-
ve behavioural therapy as it was discussed in detail 
elsewhere [5, 6]
It happens sometimes that undepressed patient 
takes an antidepressant for pain or other ailment (like 
pruritus) and after couple of hours or days discovers 
that he/she feels better, that his/her life is much more 
enjoyable. Does it mean that this person suffered of 
undiagnosed depression? Probably not. He experien-
ced mood improvement, which may precede or even 
be independent of antidepressant effect. Mood impro-
vement is usually rapid and short lived. After taking 
of some drugs it can appear within hours, but it may 
wear off in a couple of days leading to tolerance or 
even dependence (for example in case of methylpheni-
date (MPH) [7]. For a difference, antidepressant effect 
of drugs takes many days or weeks to occur, tolerance 
and dependence are rarely seen. Most antidepressant 
will with time improve the mood, but it may take many 
days or weeks before this will be obvious. 
Is mood enhancing always a good thing to do in 
terminally ill? Probably not, and it need quite a debate 
with patient and his/her family. For example, cocaine 
and amphetamines, in short term, through activation 
of the sympathetic nervous system are able to boost 
patients’ mood, energy and motivation. However, 
after an upward shift the patient may experience 
a downward one. In a critically ill patient it happened 
to me that “boosting up” his mood with methylphe-
nidate (MPH) had an opposite effect: the patient did 
not appear more aroused but appeared to be anxious 
and died sooner that expected, living us in doubt. This 
effect could be compared to kicking-up a horse that 
is lying down (healthy horses always stand, never lie 
down). Kicking it up hard may speed his death.
Another problem is that mood enhancers may 
sometimes be inappropriate and mood improvement, 
especially in the presence of depression, can be expe-
rienced by a patient an unsuitable, confusing or wrong 
behaviour. A patient with a metastasised breast cancer, 
a retired paediatrician, reported that she came back 
home after a bad-news-session in hospital in a very 
low mood. Her friend doctor gave her a tablet with 
mianserin after which her mood improved rapidly. She 
became very talkative, laughed frequently and made 
a good impression on the relieved family. However, 
afterwards she told that she felt horrible being so 
joyful in such a situation discussing with her family 
serious matters.
Finally mood enhancement may be, especially by 
older patients, associated with a wrong behaviour 
burdened by the danger of abuse and addiction. 
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imipramine [12]. This suggested for the first time that 
major depressive disorders is a highly heterogeneous 
group and MPH works on depression in a different 
way than some tryicyclics do and may be used to treat 
depression in resistant cases. Patients experienced 
mood-enhancing effect 1–3 days after commencing 
therapy. The heterogeneity of depression disorders 
and different responses to different antidepressants 
including MPH has been confirmed by other groups 
[13].
However, many of controlled clinical trials when 
MPH was compared to placebo did not confirm an-
tidepressant effect [14, 15] this despite short-term 
positive effects on mood. It appears that MPH is able 
to enhance effects of other antidepressant drugs 
like citalopram [16] but this may result in enhanced 
toxicity of the combination and even danger of the 
serotonin syndrome [17]. As it will be explained later, 
lack of effect in comparison to placebo does not ne-
cessarily means that MPH is a useless drug.
So, in conclusion. MPH is an interesting CNS sti-
mulant that shows a mood improving capacity, which 
may be independent or different from the antidepres-
sant effect. MPH is able to enhance working of other 
antidepressant drugs. The mood enhancing effect 
appears rapid, within days, but may be short lived. 
Despite negative effects of many trials MPH is worth 
to try in resistant cases of depression. 
Ketamine
Ketamine (KET) is a congener of phenylciclidine and 
is for many decennia known as a cheap dissociative 
anaesthetic. It is especially valued in the medically ill 
patients as it does not decrease blood pressure, does 
not induce bronchospasm and is generally safe with 
children. It is provided as a racemic mixture even tho-
ugh the S-isomer is known to be more potent and less 
toxic. A preparation containing only S-isomer is many 
times more expensive making it unavailable for poor 
countries. KET is believed to act on the NMDA receptor.
KET is preferentially administered IV and there 
is a controversy about the activity of KET after oral 
administration. KET has been used in subanaesthetic 
doses for the treatment of chronic pain [18]. KET 
was thought to enhance effects of opioids. Recent 
systematic reviews fail equivocally to confirm effects 
of KET in chronic pain [19, 20]. However, KET remains 
an important rescue 3rd line drug when anything else 
failed [18]. 
The mood improving ability and antidepressant ef-
fects of KET were noticed only recently [21]. This effect 
appeared long-lasting and within hours after a single 
IV dose of KET. This has been later confirmed by others 
[22, 23] Berman et al. suggested for the first time that 
the antidepressant effect of KET is using a glutami-
nergic pathway and suggested that this is why KET is 
effective in therapy resistant cases. Since this time KET 
as antidepressant developed further and a number of 
systematic analyses were performed and confirmed 
the observed effects [24–28]. KET as antidepressive 
drug is a hot topic now and some psychiatrist submit 
that KET is one of the most effective antidepressants 
ever discovered. To summarize data from numerous 
trials and analyses one can say that: KET works rapidly, 
mostly within 24 hours (mood improvement). 25% 
of patients experience remission of their depression 
within a week, but in some trials the remission rates 
are much higher. More than half of the trials (60%) 
were done with IV KET in single or repeated doses. 
IV Administration seems to be more effective than oral, 
and multiple doses (usually of 0.5 mg/kg per infusion) 
are more effective than single doses. 
Other NMDA receptor antagonists have been stu-
died too and it appears that they have less clear mood 
improving and antidepressant effect in comparison 
with KET but with decreased number of adverse ef-
fects. However, development of novel glutaminergic 
antidepressants is still possible and highly desirable. 
From the point of view of palliative care it is im-
portant that Ketamine should be probably drug of 
choice in depressed patients considering suicide. In 
this way the need of IV administration is not a barrier, 
but an advantage. 
Cannabinoids
Cannabinoids’ ability to make people happy is 
legendary and its use has been practised for recreatio-
nal purposes for centuries. It may be the most often 
used illicit drug in the world. There is some belief that 
cannabinoids use may benefit patients in chronic pain 
or spasticity that does not respond to conventional 
treatments. However, the mood improving ability is 
not well documented or trialled [29]. In fact users 
report more often feeling of wellbeing and pleasant 
clouding than a mood improvement. There are no 
data to support the antidepressant effect of cannabi-
noids. Younger individuals cherish Cannabinoids but it 
looks like the number of adverse effects is increasing 
with age [30]. So, in summary. Cannabinoids should 
not be used for their mood improving activity, espe-
cially not in older patients.
Buprenorphine
Buprenorphine (BUP) is a well know opioid anal-
gesic drug celebrating its revival after introduction 
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a decade ago of transdermal BUP. Until that time 
the drug was available only in sublingual tablets and 
parenterally. BUP is a partial μ-receptor agonist and 
antagonist of k-receptors and also displays affinity 
to other less well-known opioid receptors. It has 
a favourable safety profile especially in medically ill 
patients with poor renal and hepatic functions. With 
a careful and slow dose increase scheme it is safe in 
older people. 
Its capacity to improve mood and antidepressant 
effects were noticed long time ago [31]. However, 
serious interest in the antidepressant and mood en-
hancing effects of BUP started from the notification 
that BUP is able to help patients with therapy resistant 
depression. The mood increasing effect is quite rapid, 
within few days. Antidepressant effect will be usually 
obvious within weeks.
It seems probable that in BUP the k-antagonistic 
effects are responsible for the antidepressant effects 
[32]. BUP may also interact with serotoninergic sys-
tem. Rapid improvement of mood has been observed 
in patients with treatment resistant depression. It is 
of particular relevance for older patients who often 
are unable to tolerate tricyclic antidepressants or their 
prognosis is too short to experience it. Not unimpor-
tant is excellent analgesic effect of this drug.
The mood improving and antidepressant effect of 
BUP has been studied recently [33]. In an open label 
study BUP was prescribed to 15 older patients troubled 
by treatment resistant depression. The doses ranged 
from 0.2–1.6 mg/day (average dose 0.4 mg/day). The 
depression scores (MADRS) improved within 8 weeks 
from 27.0 +/- 7.3 to 9.5 +/-9.5. Sharp decline in de-
pression scores was observed in the first three weeks. 
There is lack of clinical trials and for systematic 
reviews we should wait a bit longer.
So, in general BUP looks to be promising new 
antidepressant with a rapid mood improving proper-
ties. The combination with a potent analgesic effect 
makes it especially attractive for Palliative Care.
Discussion
Couple of drugs, well known in Palliative Care and 
in General Medicine exert both a mood enhancing 
and antidepressant effects. None of these drugs was 
developed for this purpose and most of these drugs 
are decennia old, out of patent and poorly resear-
ched. The once so important and popular congeners 
of amphetamine (MPH) seem to be now substituted 
by KET and BUP as MPH did not show convincingly 
the antidepressant effect in systematic reviews. KET 
instead scored very high in these reviews. For BUP it 
is probably too early to decide about.
In general antidepressant drugs act upon do-
pamine and serotonin and noradrenergic system. 
Antidepressant effects of KET use the glutaminergic 
pathway (NMDA receptor) and BUP used opioidergic 
system (k-opioid receptor). Drugs my also, in short 
term influence adrenal output of cortisol. These drugs 
therefore can be used together with classical antide-
pressants or instead of them in case of drug resistance.
Cannabinoids are drugs making people happy, 
however not by enhancing their mood and antide-
pressant effect. They should not be considered here.
Neither of the drugs discussed is dangerous and 
contraindicated in medically ill patients. However, their 
use needs skilful prescribing, good information to the 
patient and monitoring. Boosting up dying patient 
who has no energy may speed up his/her death, which 
should be never the purpose of the treatment. I advise 
usually to test couple of days the drug, before they 
are needed. For example when the patient expects to 
take part in his daughter`s wedding in 6 weeks. When 
the test dose of for example MPH or KET appeared to 
improve the mood and energy level it is safe to restart 
this drug one day before wedding, but not using it all 
the time before. This may prevent tolerance develop-
ment. In case of inefficacy, there is enough time to 
look for alternatives. Instead, BUP patch can be used 
all the time and is a good alternative especially when 
analgesia is desirable.
To make confusion even more complete Pecina et 
al. [34] from the renowned group of Zubieta, studied 
effect of placebo on major depression. In a well blin-
ded cross-over design patients received two kinds of 
placebo, from which one was known to the patient as 
an “active” drug, another an “inactive” drug. “Active” 
placebo was much more effective than an inactive 
drug. The study, completed with MOR opioid binding 
studies showed that “active” placebo is associated 
with activation of the μ-opioid system in the brain. 
Many studies where candidate drugs were compared 
to placebo, may be flouted by this “active” placebo 
response. Both placebo and candidate drug may ap-
pear comparatively active which does not mean that 
the candidate drug is useless. Above implies that the 
rapid effect on mood may be the “placebo” effect of 
many drugs. Also, that treating patient with dignity 
and respect as well as paying attention to his psycho-
logical, social and spiritual issues may be effective as 
placebo and should be used all the time.
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